GWM
TARS icon

Geneos Wealth Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Geneos Wealth Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23
Closed -$932 – 3111
2025
Q2 		$932 Buy
+23
New +$1.03K ﹤0.01% 3003
2025
Q1 		– Hold
0
– – – 2939

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geneos Wealth Management's TARS Position: Q3 2025 in Review

Geneos Wealth Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 23 shares — an estimated $932 sold.

Geneos Wealth Management first reported a position in TARS in Q2 2025 and held it in 1 quarter. The position peaked at $932 in Q2 2025. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • Geneos Wealth Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 23 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $932.
  • Geneos Wealth Management first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Geneos Wealth Management's Tarsus Pharmaceuticals position peaked at $932 in Q2 2025.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.